Allogene Therapeutics, Inc. SEC filings ALLO
Allogene Therapeutics, Inc. has 585 filings in SEC EDGAR's recent list, going back to Apr 19, 2018. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 20, 2026 | — |
| EFFECT | Filing | Apr 25, 2024 | — |
| CORRESP | Letter to the SEC | Apr 23, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 19, 2024 | — |
| POSASR | Filing | Mar 14, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 29, 2024 | — |
| CORRESP | Letter to the SEC | Feb 22, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 28, 2023 | — |
| CORRESP | Letter to the SEC | Dec 15, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 21, 2023 | — |
| SC TO-I/A | Filing | Jul 20, 2022 | — |
| SC TO-I/A | Filing | Jul 12, 2022 | — |
| SC TO-I | Filing | Jun 21, 2022 | — |
| SC TO-C | Filing | Apr 14, 2022 | — |
| CT ORDER | Filing | Oct 25, 2021 | — |
| POS462B | Filing | Oct 15, 2018 | — |
| POS EX | Filing | Oct 15, 2018 | — |
| CT ORDER | Filing | Oct 11, 2018 | — |
| EFFECT | Filing | Oct 10, 2018 | — |
| CERT | Filing | Oct 10, 2018 | — |
| 8-A12B | Filing | Oct 5, 2018 | — |
| CORRESP | Letter to the SEC | Oct 4, 2018 | — |
| CORRESP | Letter to the SEC | Oct 4, 2018 | — |
| CORRESP | Letter to the SEC | Oct 2, 2018 | — |
| UPLOAD | Letter from the SEC | Sep 26, 2018 | — |
| CORRESP | Letter to the SEC | Sep 26, 2018 | — |
| CORRESP | Letter to the SEC | Sep 14, 2018 | — |
| UPLOAD | Letter from the SEC | Sep 11, 2018 | — |
| DRS | Filing | Aug 10, 2018 | — |
| D | Filing | Apr 19, 2018 | — |
Showing 30 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ALLO (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1737287
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.